The Genomics Shared Service (GSS) Is a comprehensive resource for supporting genomic studies to investigators at the University of Maryland School of Medicine, including the Marlene and Stewart Greenebaum Cancer Center (UMGCC). Services include DNA sequencing, gene expression studies, genotyping, and high-throughput DNA sequencing. GSS provides access to the informatics resources necessary to provide a seamless pathway from experimental planning and initial analysis of raw data to advanced analysis in a biological context. GSS comprises two genomic-related core laboratories supported by a third resource, the informatics resource center. Instrumentation operated by the GSS is state-of-the-art. DNA sequencing services are supported by six Applied Biosystems model 3730XL automated sequencers. High-throughput DNA sequencing is performed on two Roche 454 FLX pyrosequencers, an lllumina Genome Analyzer IIX, and an lllumina HiSeq2000. Genotyping and gene expression services are supported by an Applied Biosystems model 7900 HT Fast real-time PCR system, and lllumina BeadXpress, and Affymetrix GeneChip system 3000 7G, and an lllumina iScan. Highly skilled informatics faculty and staff provide investigators at the UMGCC with the expertise to analyze multidimensional datasets, using existing software tools, or to develop new, novel software and algorithms as necessary. A key strength of the GSS is the educational opportunities provided to students (graduate and medical) and fellows (postdoctoral and clinical) as well as faculty. These educational opportunities have a profound impact on the success the GSS has in transforming cancer research programs. The effectiveness of this shared service can be measured by the large number of publications supported annually?over 100 publications per year from members of the UMGCC alone. Many of these publications are in high-impact journals, including Cell, Proceedings of the National Academy of Sciences, Science, Nature Genetics, Cancer Research, Biochemistry, and the Journal of Molecular Biology.
The application of genomic technology to cancer research is essential in determining the molecular mechanisms involved in cancer etiology. The field of genomics will undoubtedly play a critical role in detection, treatment, and ultimately prevention of cancer.
|Appelt, Ane L; Vogelius, Ivan R; Pløen, John et al. (2014) Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys 90:110-8|
|Vogelius, Ivan R; Bentzen, Søren M (2014) Hypofractionated radiation therapy for prostate cancer: more food for thought from recent trial. J Clin Oncol 32:1852-3|
|Bao, Ting; Cai, Ling; Snyder, Claire et al. (2014) Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer 120:381-9|
|Barnett, Gillian C; Thompson, Deborah; Fachal, Laura et al. (2014) A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol 111:178-85|
|Bentzen, S M; Yarnold, J (2014) A toast to the silver anniversary of Clinical Oncology: a quarter of a century of advances in evidence-based radiation dose fractionation. Clin Oncol (R Coll Radiol) 26:599-601|
|Håkansson, Katrin; Specht, Lena; Aznar, Marianne C et al. (2014) Prescribing and evaluating target dose in dose-painting treatment plans. Acta Oncol 53:1251-6|
|Due, Anne K; Vogelius, Ivan R; Aznar, Marianne C et al. (2014) Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol 111:360-5|
|Song, Xiaomeng; Xia, Ronghui; Li, Jiang et al. (2014) Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma. Clin Cancer Res 20:701-10|
|Gojo, Ivana; Tan, Ming; Fang, Hong-Bin et al. (2013) Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res 19:1838-51|
|Natarajan, Karthika; Xie, Yingqiu; Burcu, Mehmet et al. (2013) Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One 8:e74653|
Showing the most recent 10 out of 18 publications